WARNINGS
VEMLIDY may cause serious side effects, including:
• Worsening of hepatitis B virus (HBV) infection. Your HBV infection may suddenly get worse (flare-up) if you stop taking VEMLIDY. Do not run out of VEMLIDY. Do not stop taking VEMLIDY without first talking to your healthcare provider, as they will need to check your health regularly after stopping therapy.
Tell your healthcare provider about all of your medical conditions, including if you:
• Have HIV-1 infection. Your healthcare provider may test you for HIV infection before you start using VEMLIDY. If you have both HBV and HIV, and you only take VEMLIDY, the HIV virus may develop resistance and be harder to treat.
• Have end stage renal disease (ESRD).
• Are pregnant or plan to become pregnant.
• Are breastfeeding or plan to breastfeed. VEMLIDY may pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby. Tell your healthcare provider about all the medicines you take:
• Keep a list that includes all prescription and over-the-counter medicines, vitamins, and herbal supplements, and show it to your healthcare provider and pharmacist.
• Ask your healthcare provider or pharmacist about medicines that interact with VEMLIDY.
USES
VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults and children 6 years of age and older who weigh at least 55 pounds (25 kg) with stable (compensated) liver disease. It is not known if VEMLIDY is safe and effective in children with chronic HBV infection who are under 6 years of age or weigh less than 55 pounds (25 kg). VEMLIDY:
• May lower the amount of HBV in your body.
• May improve the condition of your liver.
HOW TO USE
Take VEMLIDY 1 time each day with food.
VEMLIDY can cause serious side effects, including:
• Those in the section WARNINGS above.
• New or worse kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys when starting and during treatment with VEMLIDY.
• Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feeling dizzy or lightheaded, or a fast or abnormal heartbeat.
• Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain. The most common side effect of VEMLIDY is headache.
These are not all the possible side effects of VEMLIDY. Tell your healthcare provider right away if you have any side effect that bothers you or that does not go away.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VEMLIDY for a condition for which it was not prescribed. Do not give VEMLIDY to other people, even if they have the same symptoms that you have. It may harm them. You can ask your doctor or pharmacist for information about VEMLIDY that is written for healthcare providers.
ACTIVE INGREDIENTS: tenofovir alafenamide
Inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing: iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
OVERDOSE
Please call your healthcare provider for more information.
MISSED DOSE
Please call your healthcare provider for more information.
STORAGE
Store below 86 °F (30 °C).
• Keep container tightly closed.
• Dispense only in original container.
NOTES
Medication Guide: revision date 03/2024
Prescribing Information: revision date 03/2024
DRUG INTERACTIONS
Consult the full prescribing information for VEMLIDY for more information on potentially significant drug interactions, including clinical comments.
1.) Potential for Other Drugs to Affect VEMLIDY
VEMLIDY is a substrate of P-glycoprotein (P-gp) and BCRP. Drugs that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption (see Table 4). Drugs that induce P-gp activity are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentrations of tenofovir alafenamide, which may lead to loss of therapeutic effect of VEMLIDY. Coadministration of VEMLIDY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of tenofovir alafenamide.
2.) Drugs Affecting Renal Function
Because tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of VEMLIDY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs and this may increase the risk of adverse reactions. Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see the sections WARNINGS and PRECAUTIONS].
3.) Established and Other Potentially Significant Interactions
Table 4 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with tenofovir alafenamide or are predicted drug interactions that may occur with VEMLIDY [For magnitude of interaction, see Clinical Pharmacology (12.3)]. Information regarding potential drug-drug interactions with HIV antiretrovirals is not provided (see the prescribing information for emtricitabine/tenofovir alafenamide for interactions with HIV antiretrovirals). The table includes potentially significant interactions but is not all inclusive.
4.) Drugs without Clinically Significant Interactions with VEMLIDY
Based on drug interaction studies conducted with VEMLIDY, no clinically significant drug interactions have been observed with: ethinyl estradiol, ledipasvir/sofosbuvir, midazolam, norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir.
See the section WARNINGS above.